Human Rabies Vaccine Industry, 2013-2017 Industry size,shares,Research Trends,Growth,Study,Analysis,Forecast

Researchmoz presents this most up-to-date research on"Research Report on China Human Rabies Vaccine Industry, 2013-2017".The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

Complete Report With TOC Kindly Visit: http://www.researchmoz.us/research-report-on-china-human-rabies-vaccine-industry-2013-2017-report.html

In recent years, with increasing number of pets and the lack of strict pet management, the incidence trend of rabies in China is not optimistic. According to the survey data provided by Chinese Centers for Disease Control and Prevention (CDC), there were 130 million dogs in China by April 2012, ranking the first around the world. The death rate is approximate to 100% if people are infected with rabies viruses and contract rabies. In China, in more than 95% rabies cases, people are attacked by rabies as they are bitten by dogs. 

The problem of rabies is essentially the problem of quantity control of dogs. According to incomplete statistics, the total number of people injured by animals in 2012 was more than 40 million person-times. Most of them were bitten by dogs. In 2012, the incidence number officially provided by China government was 1,425, which decreased over 2011. However, it is possible that many rabies cases were not counted, especially in the countries where the economy is undeveloped.

In China,  rabies mainly occurs in the countryside that has poor economic conditions and medical facilities. Furthermore, the rabies tends to be further prevalent. At present, the first problem of China rabies control and prevention is the difficulty in dog management and vaccination implementation in the countryside. There are tens of millions of dogs in the countryside, but the rabies vaccination rate of dogs is less than 10%. Second, China lacks a coordination and management mechanism among departments involving in rabies control and prevention, which influences the improvement of overall rabies control and prevention effect. 

Third, China does not establish a rabies immunologic barrier. In many rural areas, many people cannot be vaccinated in time after they are bitten by dogs, because of economic problems or poor medical facilities. Among people bitten by dogs in some rural areas, only 10%-20% of them are vaccinated with rabies vaccines.

In 2012, the lot release volume of rabies vaccines in China was 80.7425 million doses (about 16.15 million person-times), increasing by about 40% YOY. As human rabies vaccines belong to Vaccine II in China, people are vaccinated at their own expenses. Therefore, rabies vaccine is one of the human vaccines that have the largest market scale in China. The terminal market scale in 2012 was over CNY 5 billion.

With the development of Chinese economy and increasing income per capita, people's health consciousness and purchase power of rabies vaccines will be growing accordingly. However, the pet management situation in most regions of China can be hardly improved in a short run. It is predicted that the number of people injured by animals (mainly by dogs) will still increase in the next few years. Therefore, the market scale of human rabies vaccines in China  will keep increasing during 2013-2017.

 

Browse All Related Reports At :  http://www.researchmoz.us/vaccines-market-reports-79.html

Through this report, readers can acquire the following information or even more:

• Development environment of China human rabies vaccines
• China rabies status overview
• Supply and demand status of China human rabies vaccines
• Major enterprises in China human rabies vaccine industry
• Factors influencing the development of China human rabies vaccine market
• Forecast on China human rabies vaccine market, 2013-2017

The following enterprises and people are proposed to purchase this report:

• Producing enterprises of human rabies vaccines
• Medical institutions
• Investors and research institutes concerned about human rabies vaccine industry

Table of Contents

1 Development Environment of China Vaccine Industry, 2008- 2012

1.1 Economic Environment

1.2 Policy Environment of Vaccine Industry

1.3 Chinese Population and the Structure

1.4 Overview on China Medical Industry

1.5 Overview on China Vaccine Market

2 Overview on China Human Rabies Vaccine Market

2.1 Epidemic Situation of Rabies in China

2.1.1 Source of Infection

2.1.2 Transmission Channel

2.1.3 Susceptible People

2.2 Rabies Vaccine Overview

2.3 Rabies Vaccine Classification

2.4 Rabies Vaccination Regulations of China National Immunization Program

3 Supply and Demand Situation of Rabies Vaccines in China , 2008-2012

3.1 Supply Status

3.1.1 Production Capacity

3.1.2 Lot Release Volume

3.2 Market Scale

4 Major Enterprises in China Human Rabies Vaccine Industry, 2010-2013

4.1 Liaoning Chengda Biotechnology Co., Ltd.

4.1.1 Enterprise Profile

4.1.2 Lot Release Volume of Human Rabies Vaccines

4.1.3 Production Capacity of Human Rabies Vaccines in 2013

4.2 Guangzhou Promise Biological Products Co., Ltd.

4.3 Liaoning Yisheng Biopharm Co., Ltd.

5 Forecast on China Human Rabies Vaccine Market, 2013-2017

5.1 Factors Influencing Industry Development

5.2 Forecast on Supply

5.3 Forecast on Demand

 

Contact Us:
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
http://www.researchmoz.us/
www.linkedin.com/company/researchmoz
https://twitter.com/researchmoz
https://www.facebook.com/pages/ResearchMoz/267379433319976

Blog: http://researchmoz.blogspot.com

Measles, Mumps and Rubella (MMR) Vaccine Industry size,shares,Research Trends,Growth,Study,Analysis,Forecast

Researchmoz presents this most up-to-date research on"Research Report on China Measles, Mumps and Rubella (MMR) Vaccine Market, 2013-2017".The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

To Read The Complete Report With TOC Kindly Visit: http://www.researchmoz.us/research-report-on-china-measles-mumps-and-rubella-mmr-vaccine-market-2013-2017-report.html

Measles, mumps and rubella are major infectious diseases that threaten the health of children. Measles is a kind of acute respiratory infectious disease caused by measles virus with rashes covering the whole body. Mumps is a kind of respiratory infectious disease caused by mumps virus, which can violate organs including various gland tissues, nervous system, liver, kidney, heart, joint, etc. Rubella is a kind of acute respiratory infectious disease caused by rubella virus with light constitutional symptoms and lymphadenectasis behind the ears and on the necks, without koplik spots.

In China, the incidence rate of measles declines constantly in recent years. In 2012, the number of measles patients was 6,183, decreasing by 37.82% YOY, with eight patients died of measles. In 2012, the incidence rate of measles was 4.6/100,000,000, which still lagged far behind the target set by WHO (incidence rate: below 1/100,000,000). In 2012, China's lot released volume of measles vaccines reached 8.651 million person-servings, decreasing by 43.5% YOY.

From 2010 to 2012, China's incidence rate of mumps increased year after year. In 2012, the number of mumps patients was 479,518, increasing by 5.53% YOY; the incidence rate was 354.1/100,000,000 without any death. In 2012, China's lot released volume of mumps vaccines was about 6.883 million person-servings, decreasing by 47% YOY.

In 2012, the number of rubella patients was 40,156 in China, decreasing by 38.74% YOY; the incidence rate was 29.7/100,000,000 and one patient died. In 2012, China's lot released volume of rubella vaccines was about 4.44 million person-servings, decreasing by 6.4% YOY.

Since domestic MMR vaccines were listed in China National Immunization Program in 2008, Chinese government has been providing eligible children with free MMR vaccines. If parents require imported MMR vaccines, it will at their own expenses.

According to long-term trend, MMR vaccines will gradually replace univalent vaccines or bivalent vaccines, becoming the mainstream in the market. During 2010 to 2012, China's lot released volume of MMR vaccines slightly declined, which mainly resulted from the fact that imported MMR vaccines were restricted. Along with the implementation of Pharmacopoeia of China (2010 Version), CFDA has not approved the MMR vaccine of GSK to be sold in China because it contains antibiotics. 

 

In 2011, a Chinese law office revealed that the MMR vaccines manufactured by Merck violated the approval process of imported vaccines in China because it lacked alerts in the specification and existed safety risks. During 2011 to 2012, China's legal import volume of MMR vaccines decreased sharply. As a result, China's total lot released volume of MMR vaccines also decreased to some extent.

In recent years, because China's newborn population is 16 million or even more every year, the prospect of MMR vaccines is promising. Although the import of MMR vaccines is restricted in China, many parents still choose imported MMR vaccines for their children out of the safety concern on domestic vaccines. These imported MMR vaccines are sold in some private clinics, which may come from smuggling.

Browse All Related Reports At : http://www.researchmoz.us/vaccines-market-reports-79.html

Through this report, readers can acquire the following information:

• Government Policies and Events in China MMR Vaccine Market
• Supply Status of MMR Vaccines in China
• Market Demand of MMR Vaccines in China
• Major Enterprises Providing MMR Vaccines in China Market
• Factors Influencing the Development of China MMR Vaccine Market
• Prospect of China MMR Vaccine Market, 2013-2017

The following enterprises and people are proposed to purchase this report:

• Vaccine Manufacturing Enterprises
• Vaccine Trade Enterprises
• Medical Institutions
• Investors and Research Institutes Concerned About Vaccine Industry

Table of Contents

1 Development Environment of China Vaccine Industry

1.1 Economic Environment

1.2 Policy Environment

1.3 Chinese Population and the Structure

1.4 Overview on China Medical Industry

1.5 Overview on China Vaccine Market

2 Overview on China MMR Vaccine Market, 2010-2012

2.1 Epidemic Situation of Measles, Mumps and Rubella in China

2.1.1 Measles

2.1.2 Mumps

2.1.3 Rubella

2.2 MMR Vaccine Overview

2.3 Rules on Vaccination Procedures of China National Immunization Program

3 Overview on China MMR Vaccine Market, 2010-2012

3.1 Status of Lot Release

3.1.1 Measles Vaccine

3.1.2 Mumps Vaccine

3.1.3 Rubella Vaccine

3.1.4 MMR Vaccine

3.2 Market Scale

4 Major Manufacturing Enterprises in China MMR Vaccine Market, 2010-2013

4.1 Shanghai Institute of Biological Products Co., Ltd. (SIBP)

4.1.1 Enterprise Profile

4.1.2 Lot Released Volume of MMR Vaccine

4.1.3 Production Capacity of MMR Vaccine in 2013

4.2 Beijing Tiantan Biological Products Co., Ltd.

4. 2.1 Enterprise Profile

4.2.2 Lot Released Volume of MMR Vaccine, 2010-2012

4.2.3 Production Capacity of MMR Vaccine in 2013

4.3 Other Enterprises

5 Forecast on China MMR Vaccine Market, 2013-2017

5.1 Factors Influencing Development

5.2 Forecast on Supply, 2013-2017

5.3 Forecast on Market Demand, 2013-2017

Contact Us:
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
http://www.researchmoz.us/
www.linkedin.com/company/researchmoz
https://twitter.com/researchmoz
https://www.facebook.com/pages/ResearchMoz/267379433319976

Blog: http://researchmoz.blogspot.com

U.S.Cord Blood Banking Industry Report 2013-14 - Researchmoz.us

Researchmoz presents this most up-to-date research on"U.S.Cord Blood Banking Industry Report 2013-14".The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

To Read The Complete Report With TOC Kindly Visit: http://www.researchmoz.us/uscord-blood-banking-industry-report-2013-14-report.html

PART 1: U.S. Cord Blood Banking Industry - Market Overview & Outlook

Stem cells derived from umbilical blood have been used in more than 30,000 transplants worldwide to treat a wide range of blood diseases, genetic and metabolic disorders, immunodeficiencies and various forms of cancer. Additionally, cord blood banks now exist in nearly every developed country, as well as several developing nations. However, there is still significant variation within the industry.

First, there is the divide between private and public cord blood banking, in which private companies serve individual families, while public banks serve the broader public. Additionally, some cord blood banks receive only units from nearby hospitals and birthing centers, while others allow mail-in units from a wide geographic region. There is also variation in the services offered by private cord blood banks, with cord tissue storage emerging as a commercial service in 2010, when the Cord Blood Registry began offering it, to complement its cord blood banking services. This trend of cord tissue storage has had a significant impact on the cord blood banking industry, with nine private U.S. companies now offering the service. Finally, there is also significant variation in the quality, pricing, and guarantees promised by U.S. cord blood banks.

This section of the report considers the impact of historical events, the importance of key findings and discoveries on market conditions, and rapidly changing aspects of the industry. It is a roadmap of where the cord blood banking industry has been, what has shaped it, and where it is going. With an understanding of these relevant market conditions, the subsequent sections of this report become “rooted” and relevant.

PART 2: Expansion & Growth – Trailing 12-Month Analysis and Future Projections

While last section “rooted” where the cord blood banking industry has been and what has shaped it, this section explores where it is now and what you can anticipate for the near-term future. It provides a detailed assessment of current market conditions and near-term projections.

This section is dedicated to revealing, quantifying, and extrapolating industry trends, for the purpose of giving meaning projections for the future. It is your guide to understanding expansion and growth within the U.S. cord blood banking industry.

View All Related Reports At : http://www.researchmoz.us/healthcare-market-reports-56.html

PART 3: Parent Survey – Continuing to Grow by Listening to Expectant Parents

To recap, the first section of the report “roots” where the cord blood banking industry has been and what has shaped it. The second section explores where it is now and what you should anticipate for the near-term future, and provides a detailed assessment of current market conditions and near-term projections. Most importantly, the previous section shows you what to expect if trends continue as they are; it reveals the environment that you will find yourself in if you don’t take strategic action.

This final section of the report is now your roadmap to the future. It is your guide to taking strategic action and controlling your competitive position as a U.S. cord blood bank.

This section contains findings from a detailed parent survey that reveal how expectant parents within the United States learn about cord blood banking, think about the process, and make key decisions. This survey is your insight into the minds of your prospective clients. Use it to claim powerful control over your ability to sell your services more effectively.

You can use the findings revealed here to:

• Alter the way you position your products
• Understand why parents bank publicly, privately, or not at all
• Communicate successfully with parents
• Effectively educate parents
• Prioritize your advertising budget
• Sell your services more effectively 

In summary, this section is your guide to growing, expanding, and profiting, by listening to the needs of your clients – expectant parents.

Overview

The cord blood banking industry is one of the fastest growing industries in the world. There were only 23 active cord blood banks as of 2005, and now there are 485 worldwide. Cord blood banks now exist in nearly every developed country, as well as within several developing nations. That is a 21-fold increase (2,100%) in the companies involved in the industry in less than a ten-year period.

Within the United States, cord blood banks have appeared in nearly every state. Furthermore, the U.S. cord blood banking industry is the most mature cord blood banking market in the world, having the:

• First company to offer cord blood storage (1995)
• Early entrant into cord tissue storage (2010)
• Largest total number of industry participants (both public and private)
• Most number of cord blood units (CBU) stored
• Most cord blood units banked proportional to population 

This rapid market growth represents both an opportunity to profit, as well as swarming competition. 

A Fast-Growth Industry, Driven by Medical Necessity and Consumer Demand

The field of cord blood banking is a fast-growth field, driven by medical necessity and consumer demand. It is also a recent industry, as it was not until 1974 that it was first proposed that stem and progenitor cells were present in human cord blood and 1983 that umbilical cord blood was proposed as an alternative source of stem cells for transplant. In 1988, the first successful cord blood transplant occurred, but it was not until 1995 that the first private cord blood bank began operations.

Furthermore, it was not until July, 2010, when the Cord Blood Registry became the first private U.S. cord blood bank to offer umbilical cord tissue storage. In the two years that have since passed then, the number of private U.S. cord blood banks offering cord tissue storage has risen to nine. This represents an average of one new U.S. cord blood bank adding cord tissue storage every 3 months. If this rate continues, half of all private U.S. cord blood banks will offer cord tissue storage within two years.

Since the first cord blood transplant was performed in 1988, stem cells derived from umbilical blood have been used in more than 30,000 transplants worldwide to treat a wide range of blood diseases, genetic and metabolic disorders, immunodeficiencies and various forms of cancer. However, there is still significant variation within the industry. There is the divide between private and public cord blood banking, in which private companies serve individual families, while public banks serve the broader public. Additionally, some cord blood banks receive only units from nearby hospitals and birthing centers, while others allow mail-in units from a wide geographic region.

There is also variation in the services offered by private cord blood banks, as some companies only offer cord blood storage only and others offer it in conjunction with cord tissue storage. Finally, there is also significant variation in the quality, pricing and guarantees promised by cord blood banks.

Contact Us:M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
http://www.researchmoz.us/
www.linkedin.com/company/researchmoz
https://twitter.com/researchmoz
https://www.facebook.com/pages/ResearchMoz/267379433319976

Blog: http://researchmoz.blogspot.com

Obesity Therapeutics to 2019 Available At Researchmoz.us

Researchmoz presents this most up-to-date research on"Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity".The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

To Read The Complete Report With TOC Kindly Visit: http://www.researchmoz.us/obesity-therapeutics-to-2019-safety-concerns-hinder-drug-performance-despite-large-market-opportunity-report.html

Leading business intelligence provider, has released its latest research: Obesity Therapeutics to 2019 – Safety Concerns Hinder Drug Performance Despite Large Market Opportunity”. Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs.

Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market. 

Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and GBI Research believes that only one, Vivus’ Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies.

If proven safe, GBI Research expects the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals’ negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity.

Browse All Related Reports At : http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Scope

The report analyzes the incidence of obesity, current treatment options, pipeline and market forecasts, and deals surrounding anti-obesity drugs.

The report includes:

•  A brief introduction to obesity; detailed analysis of recent, current and projected incidence trends; co-morbidities; economic implications of their treatment; and the current treatment options
• Analysis of the currently marketed anti-obesity drugs, including recent sales figures, safety and efficacy data, and a discussion of each drug’s expected performance within the forecast period
• Comprehensive reviews of the pipeline for anti-obesity drugs, including analysis by molecule type and mechanism of action
• Statistical analysis of clinical trial duration, size, and failure rate by Phase and molecule type
• An in-depth forecast model for the anti-obesity drugs market in the US, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated market performance of marketed drugs and those expected to be approved within the forecast period, and takes into account drug cost, efficacy, safety, and likely prescription volumes.
• A detailed discussion of the drivers and barriers for this immature market

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

• Understand the large number of potential molecular targets for the development of an anti-obesity drug, as well as the strengths, weaknesses, and risks of each drug type
• Gain an in-depth view of the current status of the anti-obesity drug pipeline, including the most common molecular targets and molecule types in development
• Observe the trends in clinical trial duration and size by Phase, molecule type and mechanism of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and future developmental programs
• Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the anti-obesity drugs market
• Analyze current and past deals surrounding anti-obesity drugs, including their value, year of deal and in depth details of the highest value deals

Contact Us:M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
http://www.researchmoz.us/
www.linkedin.com/company/researchmoz
https://twitter.com/researchmoz
https://www.facebook.com/pages/ResearchMoz/267379433319976
Blog: http://researchmoz.blogspot.com